Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383861 | 0.83 | HIF1A (0.64) | HIF1A | |
| SCHEMBL10676787 | 0.83 | EGFR (0.70) | CYP19A1NQO2EGFRSRCALDH1A1 | |
| SCHEMBL12254449 | 0.83 | HIF1A (0.53) | CYP19A1NQO2EGFRSRCKDM4E | |
| SCHEMBL2382224 | 0.83 | HIF1A (0.53) | CYP19A1NQO2EGFRSRCKDM4E | |
| SCHEMBL2384824 | 0.81 | L3MBTL1 (0.49) | CYP19A1NQO2EGFRSRCALDH1A1 | |
| SCHEMBL15419065 | 0.81 | EGFR (0.47) | CYP19A1NQO2EGFRSRCKDM4E | |
| SCHEMBL12254448 | 0.81 | L3MBTL1 (0.47) | CYP19A1NQO2EGFRSRCALDH1A1 | |
| SCHEMBL2384819 | 0.81 | L3MBTL1 (0.49) | CYP19A1NQO2EGFRSRCALDH1A1 | |
| SCHEMBL2383867 | 0.81 | L3MBTL1 (0.47) | CYP19A1NQO2EGFRSRCALDH1A1 | |
| SCHEMBL2383869 | 0.81 | L3MBTL1 (0.47) | CYP19A1NQO2EGFRSRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960363-B1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-1960363-B1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007070359-A2 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | CYP19A1 108/4885NQO2 7/4885EGFR 4278/4885 |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | CYP19A1 87/4885NQO2 7/4885EGFR 4080/4885 |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | EGLN3, HIF1AN, EGLN2 | CYP19A1 87/4885NQO2 7/4885EGFR 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.